智能手机干预优化阿片类药物使用障碍的药物治疗结局:一项随机对照试验的研究方案
本研究为双臂单盲随机对照试验,在阿肯色州小石城地区门诊接受阿片类药物使用障碍药物治疗(MOUD)的成人中,评估辅助使用智能手机应用OptiMAT减少阿片类药物误用的效果,并分析特定功能(如GPS即时干预)的作用。主要结局为入组后6个月内通过盲法尿检确定的阿片类药物误用差异。
要点
- 辅助使用OptiMAT可能改善MOUD结局,但尚待本试验验证。
- 研究采用1:1随机区组设计,分组为MOUD+OptiMAT与单纯MOUD。
- 主要结局为6个月内阿片类药物误用,由盲法尿检确定。
核心结论
- 本试验将检验辅助使用OptiMAT是否能改善MOUD结局。
- 研究结果可能支持将OptiMAT扩展至农村临床环境,并识别最能预测阳性临床结局的OptiMAT功能,从而优化此类智能手机应用干预。
研究设计与样本
- 研究为双臂、单盲、随机对照试验,对象为在阿肯色州小石城地区门诊接受MOUD的英语成人(年龄18岁及以上),近期入组参与研究诊所。
- 参与者按1:1随机区组设计分配至MOUD+OptiMAT组或单纯MOUD组。
主要发现
- 原文为研究方案,尚未报告试验结果。
关键数值与推荐
- 主要分析比较两组在入组后6个月内阿片类药物误用的差异,误用由临床实验室人员以盲法进行定量尿液分析确定。
- 次要分析评估MOUD+OptiMAT组内OptiMAT使用模式是否能预测阿片类药物误用或持续戒断。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Opioids accounted for 75% of drug overdoses in the USA in 2020, with rural states particularly impacted by the opioid crisis. While medication-assisted treatment (MAT) with Suboxone remains one of the more efficacious treatments for opioid use disorder (OUD), approximately 40% of people receiving Suboxone for outpatient MAT for OUD (MOUD) relapse within the first 6 months of treatment. We developed the smartphone app-based intervention OptiMAT as an adjunctive intervention to improve MOUD outcomes. The aims of this study are to (1) evaluate the efficacy of adjunctive OptiMAT use in reducing opioid misuse among people receiving MOUD and (2) evaluate the role of specific OptiMAT features in reducing opioid misuse, including the use of GPS-driven just-in-time intervention. METHODS: We will conduct a two-arm, single-blind, randomized controlled trial of adults receiving outpatient MOUD in the greater Little Rock AR area. Participants are English-speaking adults ages 18 or older recently enrolled in outpatient MOUD at one of our participating study clinics. Participants will be allocated via 1:1 randomized block design to (1) MOUD with adjunctive use of OptiMAT (MOUD+OptiMAT) or (2) MOUD without OptiMAT (MOUD-only). Our blinded research statistician will evaluate differences between the two groups in opioid misuse (as determined by quantitative urinalysis conducted by clinical lab staff blinded to group membership) during the 6-months following study enrolment. Secondary analyses will evaluate if OptiMAT-usage patterns within the MOUD+OptiMAT group predict opioid misuse or continued abstinence. DISCUSSION: This study will test if adjunctive use of OptiMAT improve MOUD outcomes. Study findings could lead to expansion of OptiMAT into rural clinical settings, and the identification of OptiMAT features which best predict positive clinical outcome could lead to refinement of this and similar smartphone app-based interventions. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT05336188 , registered March 21, 2022.
引用
- Thompson RG, Bollinger M, Mancino MJ, et al. Smartphone intervention to optimize medication-assisted treatment outcomes for opioid use disorder: study protocol for a randomized controlled trial. Trials. 2023. PMID: 37016394. doi:10.1186/s13063-023-07213-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。